Acacia Pharma Expands US Commercial Operations for BAREMSIS® with Four Key Appointments
Cambridge, UK and Indianapolis, US : Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has made substantial progress in expanding its US commercial operations for the intended launch of intravenous amisulpride (BAREMSIS®) with four key appointments. The new hires bring significant and relevant commercial experience in launching and marketing hospital pharmaceutical products in the US and have been recruited, as planned, ahead of the target PDUFA date for BAREMSIS of 5 October 2018.
Mike Bolinder, Chief Commercial Officer of the Group’s US subsidiary, Acacia Pharma, Inc., commented: “Filling these key roles with these experienced leaders with such relevant experience provides the Group with a strong foundation for the intended US commercialisation of BAREMSIS. We are delighted to welcome them all to the team and look forward to getting our launch preparations underway. It is a great achievement for Acacia Pharma to attract such high calibre professionals, and to deliver the first key element of our commercialisation strategy so soon after completing our recent Initial Global Offering.”Back to News